Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Common Equity (2021 - 2026)

HeartSciences (HSCS) has disclosed Common Equity for 5 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 4.13% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Oct 2025, up 4.13%, and an annual FY2025 reading of $205171.0, down 97.2% over the prior year.
  • Common Equity was $4.2 million for Q4 2025 at HeartSciences, up from $3.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $8.6 million in Q1 2024 and bottomed at -$6.1 million in Q2 2022.
  • Average Common Equity over 5 years is $1.2 million, with a median of $656616.5 recorded in 2022.
  • The sharpest move saw Common Equity crashed 252.37% in 2023, then surged 3447.59% in 2024.
  • Year by year, Common Equity stood at -$3.4 million in 2021, then skyrocketed by 131.45% to $1.1 million in 2022, then plummeted by 252.37% to -$1.6 million in 2023, then surged by 343.48% to $4.0 million in 2024, then increased by 4.13% to $4.2 million in 2025.
  • Business Quant data shows Common Equity for HSCS at $4.2 million in Q4 2025, $3.1 million in Q3 2025, and $205171.0 in Q2 2025.